

Dealdoc

Contract service agreement for imaging and instrumentation capabilities

BIOLIFE4D Northwestern University

Feb 05 2018

Contract service agreement for imaging and instrumentation capabilities

Companies:

Announcement date:

Deal value, US\$m:

resources, including its sophisticated imaging and instrumentation capabilities.

© 2025 Biopharma Research Ltd. All rights reserved.

• Details

Financials

Termsheet

Filing Data

Contract

Details

Press Release

BIOLIFE4D

Feb 05 2018

n/d

Northwestern University

Announcement date:	Feb 05 2018
	Academic
Industry sectors:	Research tools
	Services
Asset type:	Facilities
	Technology
Therapy areas:	Cardiovascular
	Hospital care » Transplantation
	Devices
Technology types:	Diagnostics » Imaging
	Implant
Deal components:	Contract service
Financials	
Deal value, US\$m:	n/d
Termsheet	
BIOLIFE4D has signed a Laboratory Service Agreement with Northwestern University.	
The LSA provides the Company access to Northwestern's world class shared and core academic research facilities and resources, including its	
sophisticated imaging and instrumentation capabilities.	
Access to those care facilities and laboratory equipment will play a critical rale as PIOLIEE 4D continues the development of its inneventure	
Access to these core facilities and laboratory equipment will play a critical role as BIOLIFE4D continues the development of its innovative	
technology and its core mission of being able to 3D bioprint a viable human heart for transplant.	
The Company will utilize the same resources that are pivotal to Northwestern's research infrastructure that helps to facilitate groundbreaking	
science.	
Press Release	
BIOLIFE4D Signs Laboratory Service Agreement With Northwestern University	
DIOLIT LAD OIGHS LADORATORY DELYICE AGREEMENT WHITH MOTH WESTERN OF INVESTIGN	
CHICAGO, Feb. 05, 2018 (GLOBE NEWSWIRE) BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human	
organs viable for transplant, today announced it has signed a Laboratory Service Agreement ("LSA") with Northwestern University	
("Northwestern"). The LSA provides the Company access to Northwestern's world class shared and core academic research facilities and	

Access to these core facilities and laboratory equipment will play a critical role as BIOLIFE4D continues the development of its innovative technology and its core mission of being able to 3D bioprint a viable human heart for transplant. The Company will utilize the same resources that are pivotal to Northwestern's research infrastructure that helps to facilitate groundbreaking science.

"We are honored to have the opportunity to utilize laboratory resources from the prestigious Northwestern University, where such groundbreaking scientific work has occurred. The importance of these resources to a pioneering biotech company really cannot be understated," said Steven Morris, CEO, BIOLIFE4D. "This is a tremendous opportunity for our Company as we continue to develop our technology. Not only will it provide us access to world class labs, but it also enables us to utilize the most advanced, state-of-the-art equipment, staff, and facilities at these leading research centers. We want to change the world and are now better suited to do so."

Through the LSA, BIOLIFE4D will have access to facilities at Northwestern's Evanston and Chicago campuses, Argonne National Laboratory, and Northwestern Memorial Hospital, as well as the University of Chicago and University of Illinois at Chicago through Northwestern's partnership in the Open Access Initiative.

To see how BIOLIFE4D's process starts with a patient's own cells and ends with a functional human heart ready for transplant, please watch this video.

To learn more about BIOLIFE4D and to express interest in investing please watch this video or visit https://biolife4d.com/invest/.

Securities are offered pursuant to a Regulation A+. Investors are encouraged to read the Offering Circular and exhibits and consult with their tax, legal, or financial professional prior to investing.

About BIOLIFE4D

BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully

runctioning heart will be created through 3D biophinting using the patient's own cells – eliminating the well-known challenges of organ rejection	
and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a	
movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and investigations are considered to transform the treatment of heart disease, the leading cause of death among both men and women globally.	
at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.	

Filing Data

Not available.

Contract

Not available.